摘要
胰高糖素样肽1(GLP-1)受体激动剂和二肽基肽酶-4(DPP-4)抑制剂是近年上市的治疗2型糖尿病的新型药物。GLP-1主要通过抑制心肌细胞凋亡、改善内皮细胞功能、减轻体重、降低血糖、降低血压、改善心肌收缩力、舒张血管等直接或间接发挥其心脏保护作用,GLP-1受体激动剂和DPP-4抑制剂对体重、血压和血脂等心血管危险因素有改善作用。GLP-1受体激动剂和DPP-4抑制剂作用于新靶点,具有其独特的优点,将会是一类抗糖尿病新药。
Glucagon-like Peptide-1 （GLP-1） receptor agonists and dipeptidyl peptidase-4 （DPP-4） inhibitors are new kinds of drugs to treat type 2 diabetes mellitus. It was demonstrated that GLP-1 has an obvious cardioprotective effect mainly achieved by relaxing vascular vessels, improving endothelial function, improving endothelial function and promoting the functional recovery of pathological ventricle, which can directly or indirectly protect the heart. GLP-1 receptor agonists and DPP4 inhibitors also showed important effects on the body weight, blood pressure, lipids, and other cardiovascular risk factors. GLP-1 receptor agonists and DPP4 inhibitors have more advantages than other anti-diabetes drugs because they act on a new target. They will be a useful new class of anti-diabetes drugs.
出处
《临床药物治疗杂志》
2013年第4期42-46,共5页
Clinical Medication Journal
